Phase 2a Study Shows BTX 1801 Eradicates Staphylococcus Aureus
•Top-line data showed that two different BTX 1801 formulations (ointment and gel) were safe, well tolerated and successful at eradicating Staphylococcus aureus.
•Eradication rates as high as 76.2% were obtained at Day 7 for BTX 1801 ointment, with eradication effects extending through to Day 28 of the study to 23.8%, despite no treatment after Day 5
•Botanix continues to assess the clinical utility of synthetic CBD for the treatment of a variety of infections and also develop its proprietary CBD analog assets
Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-7
-
- There are more pages in this discussion • 581 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
0.005(3.45%) |
Mkt cap ! $294.1M | |||
| Open | High | Low | Value | Volume |
| 14.5¢ | 15.0¢ | 14.3¢ | $2.536M | 17.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 1531475 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 2144586 | 28 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |